A German man, known as Berlin 2 (B2), remains in remission from HIV six years after a stem cell transplant, marking the seventh known long-term remission case.
The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...
Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...
Regeneron Pharmaceuticals Inc. and Tessera Therapeutics Inc. have announced a global collaboration to develop and ...
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive degradation of brain cells, as well ...
TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...
Pharmaceutical Technology on MSN
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
A new FDA pathway could speed bespoke gene therapies, but key questions over scope and commercial viability remain.
As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
Research is important to us for many reasons. Sometimes, for example, research results in a new treatment (e.g., Alexander ...
But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...
Tech-savvy parents to be are using IVF and screening embryos to build families in ways that were unimaginable a few short years ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback